Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥68.00
¥1.00(1.52%)
At close: 4:00 PM EDT
¥68.00
¥1.00(1.52%)
Day’s Range― - ―
52-Week Range¥65.00 - ¥229.00
Previous CloseN/A
Volume398.00K
Average Volume (3M)577.10K
Market Cap
¥5.69B
Enterprise Value¥5.12K
Total Cash (Recent Filing)¥977.18M
Total Debt (Recent Filing)¥832.50M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-100.06
Shares Outstanding80,228,210
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Pharma FocusA specialty and oncology focus can support differentiated product positioning and deeper expertise in targeted markets. This may create more durable commercial opportunities than a broad, undifferentiated portfolio, although future benefits depend on successful development and commercialization.
Strong Gross MarginStrong gross margin indicates that approved products may retain attractive economics after direct production costs. This provides a foundation for recovery if sales improve or operating expenses are controlled, though it has not yet offset the company’s broader cost burden.
Multiple Revenue ChannelsThe business model can combine direct product sales with collaboration income, royalties, milestones, and licensing. This structure may broaden monetization options and reduce reliance on one channel, while outcomes remain dependent on product rights, partners, and development progress.
Bears Say
Multi-Year Revenue DeclineRepeated revenue contraction signals weakening commercial scale and limits the company’s ability to absorb fixed research, selling, and administrative costs. Continued declines could impair product investment, reduce operating leverage, and make a return to sustainable profitability more difficult.
Persistent Losses And Cash BurnSustained operating losses combined with negative operating and free cash flow show that the business is not currently self-funding. If this persists, management may need additional financing or cost reductions, potentially limiting development capacity and increasing liquidity risk.
Rising Leverage And Equity ErosionNew debt alongside compressed equity reduces financial flexibility and increases dependence on future operating improvement or external funding. A more leveraged balance sheet can constrain investment in the pipeline and heighten the impact of continued losses on solvency and liquidity.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥65.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥5.69B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Oct 29, 2026 which is in 73 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on Jul 30, 2026. The company reported -¥15 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 80,228,210 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―